, Rigel Pharmaceuticals
, Sight Sciences
, and Twist Biosciences
were included in the Financial Times’ list of fastest-growing companies
across the Americas.
was granted Fast Track designation by the FDA for
, its allogenic CAR-T cell therapy for relapsed or refractory multiple myeloma.
launches with $50 million in Series A funding
was named one of the World’s Most Innovative Companies by Fast Company
in its 16th annual awards.
’ investigational targeted protein degrader candidate NX-0479, which has potential in the treatment of rheumatoid arthritis and other inflammatory diseases, was licensed by Gilead Sciences for $20 million
. Nurix could potentially receive up to an additional $425 million in clinical, regulatory, and commercial milestone payments.
, a company specializing in AI for mapping patients’ disease trajectories, published their product capabilities
to accurately predict length-of-stay and risk of mortality in the intensive care unit with 85% precision.
raised an additional $10 million in equity
to continue its development of proprietary methods in genomic sequencing, artificial intelligence and synthetic biology.
is partnering with Regeneron in a $75 million deal to develop cell therapies
to treat Chron’s disease and other autoimmune conditions.
, which is developing novel antibody cancer drugs, raised $2.2 million
in seed round funding.
dosed the first participants in its Phase 2 study of VAX-24
in healthy infants. The study will evaluate the safety, tolerability and immunogenicity of VAX-24, a broad-spectrum 24-valent pneumococcal conjugate vaccine candidate to prevent invasive pneumococcal disease.
new CEO, Marianne De Backer, was recently profiled in Endpoint News
about what’s on the horizon for the drugmaker.